December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Stephen V Liu: Cardiotoxicity of osimertinib in real world population with EGFR NSCLC
Oct 13, 2024, 07:07

Stephen V Liu: Cardiotoxicity of osimertinib in real world population with EGFR NSCLC

Stephen V Liu shared on X:

“Cardiotoxicity of osimertinib in real world population with EGFR NSCLC. In 1126 patients, incidence of osimertinib-related cardiac dysfunction was 4.7% (3.4% required some intervention). Recovery rate was 82.4% (similar if discontinued or not).”

The Risk and Reversibility of Osimertinib-related Cardiotoxicity in a Real-World Population | Journal of Toracic Oncology

Authors: Minjung Bak, Hyukjin Park, Se-Hoon Lee, Nuri Lee, Myung-Ju Ahn, Jin Seok Ahn, Hyun Ae Jung, Sehhoon Park, Jinhyun Cho, Jihoon Kim, Sung-Ji Park, Sung-A Chang, Sang-Chol Lee, Seung Woo Park,  Eun Kyoung Kim, 

Stephen V Liu: Cardiotoxicity of osimertinib in real world population with EGFR NSCLC

Luis Raez shared this post, adding:

“Very interesting data we dont really know what is the real incidence and its hard because before to blame osimertinib we need to rule out CAD and other causes. Also every patient should have an Echo before to start osimertinib.”

More posts featuring Stephen V Liu on oncodaily.com

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Luis E. Raez is the Medical Director and Chief Scientific Officer at Memorial Cancer Institute, part of Memorial Healthcare System. He specializes in treating lung and head and neck cancers and leads the Thoracic Oncology Program as Director.

Dr. Raez is also a clinical professor of medicine at Florida International University (FIU), a research professor at Florida Atlantic University (FAU), and a visiting professor of medicine at Cayetano Heredia University (UPCH) in Peru.